Human mesenchymal stem cells increases expression of α-tubulin and angiopoietin 1 and 2 in focal cerebral ischemia and reperfusion

Current Neurovascular Research

Volumn 10, Issue 2, 2013, Pages 103-111

  Ma, Xue Ling ^a   Liu, Kang Ding ^a   Li, Fu Chun ^a   Jiang, Xin Mei ^b   Jiang, Lai ^c   Li, Hu Lun ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Angiogenesis; Angiopoietin 1; Angiopoietin 2; Cerebral ischemia and reperfusion; tubulin

Indexed keywords

ALPHA TUBULIN; ANGIOPOIETIN 1; ANGIOPOIETIN 2; BETA1 INTEGRIN; CD34 ANTIGEN; CD45 ANTIGEN; HERMES ANTIGEN; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; BRAIN ISCHEMIA; CONTROLLED STUDY; FOLLOW UP; HIPPOCAMPUS; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REPERFUSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

EID: 84879831533     PISSN: 15672026     EISSN: 18755739     Source Type: Journal    
DOI: 10.2174/1567202611310020003     Document Type: Article

References (31)

1. Dobolyi A, Vincze C, Pál G, Lovas G. The neuroprotective functions of transforming growth factor Beta proteins. Int J Mol Sci 2012; 13(7): 8219-58.
2. Sellke FW, Simons M. Angiogenesis in cardiovascular disease: current status and therapeutic potential. Drugs 1999; 58(3): 391-6.
3. Zacharek A, Chen J, Cui X, et al. Angiopoietin1/Tie2 and VEGF/Flk1 induced by MSC treatment amplifies angiogenesis and vascular stabilization after stroke. J Cereb Blood Flow Metab 2007;27(10): 1684-91.
4. Davis S, Aldrich TH, Jones PF, et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996;87(7): 1161-9.
5. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407(6801): 242-8.
6. Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997;277(5322): 55-60.
7. Morris PN, Dunmore BJ, Tadros A, et al. Functional analysis of a mutant form of the receptor tyrosine kinase Tie2 causing venous malformations. J Mol Med (Berl) 2005;83(1): 58-63.
8. Shim WS, Ho IA, Wong PE. Angiopoietin: a TIE(d) balance in tumor angiogenesis. Mol Cancer Res 2007; 5(7): 655-65.
9. Lin TN, Wang CK, Cheung WM, Hsu CY. Induction of angiopoietin and Tie receptor mRNA expression after cerebral ischemia-reperfusion. J Cereb Blood Flow Metab 2000; 20(2): 387-95.
10. Wang RG, Zhu XZ. Expression of angiopoietin-2 and vascular endothelial growth factor in mice cerebral cortex after permanent focal cerebral ischemia. Acta Pharmacol Sin 2002; 23(5): 405-11.
11. Brock CS, Lee SM. Anti-angiogenic strategies and vascular targeting in the treatment of lung cancer. Eur Respir J 2002; 19(3): 557-70.
12. Huang Z, Bao SD. Roles of main pro-and anti-angiogenic factors in tumor angiogenesis. World J Gastroenterol 2004; 10(4): 463-70.
13. Suri C, McClain J, Thurston G, et al. Increased vascularization in mice overexpressing angiopoietin-1. Science 1998;282(5388): 468-71.
14. Valable S, Bellail A, Lesné S, et al. Angiopoietin-1-induced PI3-kinase activation prevents neuronal apoptosis. FASEB J 2003;17(3): 443-5.
15. Loughna S, Sato TN. Angiopoietin and Tie signaling pathways in vascular development. Matrix Biol 2001; 20(5-6): 319-25.
16. Fiedler U, Scharpfenecker M, Koidl S, et al. The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood 2004;103(11): 4150-6.
17. Lobov IB, Brooks PC, Lang RA. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci USA 2002; 99(17): 11205-10.
18. Cai M, Zhang H, Hui R. Single chain Fv antibody against angiopoietin-2 inhibits VEGF-induced endothelial cell proliferation and migration in vitro. Biochem Biophys Res Commun 2003; 309(4): 946-51.
19. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284(5411): 143-7.
20. Liu JF, Wang BW, Hung HF, Chang H, Shyu KG. Human mesenchymal stem cells improve myocardial performance in a splenectomized rat model of chronic myocardial infarction. J Formos Med Assoc 2008; 107(2): 165-74.
21. Bang OY, Lee JS, Lee PH, Lee G. Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol 2005; 57(6): 874-82.
22. Shen LH, Li Y, Chen J, et al. Therapeutic benefit of bone marrow stromal cells administered 1 month after stroke. J Cereb Blood Flow Metab 2007;27(1): 6-13.
23. Bao X, Wei J, Feng M, et al. Transplantation of human bone marrow-derived mesenchymal stem cells promotes behavioral recovery and endogenous neurogenesis after cerebral ischemia in rats. Brain Res 2011;1367: 103-13.
24. Wakabayashi K, Nagai A, Sheikh AM, et al. Transplantation of human mesenchymal stem cells promotes functional improvement and increased expression of neurotrophic factors in a rat focal cerebral ischemia model. J Neurosci Res 2010;88(5): 1017-25.
25. Ma XL, Yang W, Jiang XM, et al. Specific protein expression in a rat model of early focal cerebral ischemia-fluorescent two-dimensional difference gel electrophoresis. Neural Regen Res 2010;5(3): 209-13.
26. Longa Z, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniotomy in rats. Stroke 1989; 20(1): 84-91.
27. Ma XL, Wang XR, Jiang XM, Chen BZ, Li X, Liu KD. Behavioral changes in rats with focal cerebral ischemia after directional transplantation of bone marrow mesenchymal stem cells. J Clin Rehabilitative Tissue Eng Res 2008; 3(3): 578-82. (in Chinese)
28. Beck H, Acker T, Wiessner C, Allegrini PR, Plate KH. Expression of angiopoietin-1, angiopoietin-2, and tie receptors after middle cerebral artery occlusion in the rat Am J Pathol 2000; 157(5): 1473-83.
29. Onda T, Honmou O, Harada K, Houkin K, Hamada H, Kocsis JD. Therapeutic benefits by human mesenchymal stem cells (hMSCs) and Ang-1 gene-modified hMSCs after cerebral ischemia. J Cereb Blood Flow Metab 2008; 28(2): 329-40.
30. Toyama K, Honmou O, Harada K, et al. Therapeutic benefits of angiogenetic gene-modified human mesenchymal stem cells after cerebral ischemia. Exp Neurol 2009;216(1): 47-55.
31. Zheng W, Honmou O, Miyata K, et al. Therapeutic benefits of human mesenchymal stem cells derived from bone marrow after global cerebral ischemia. Brain Res 2010;1310: 8-16.